Objective

The purpose of this overview of osteoarthritis (OA) biomarkers is to provide the non-specialist with a toolbox, based on experience acquired by biomarker researchers over many years, to understand biomarkers in general and their use in the OA field.

Methods

We provide an update on this subject since the OARSI Primer on osteoarthritis (OA) nearly a decade ago.

Results

Since the last update, the importance of molecular biomarkers has been increasingly recognized in the field, but no OA-related biomarkers have been adopted for routine use in clinical practice. The current lack of chondroprotective treatments for OA impairs the assessment, validation and qualification of the potential role of biomarkers as tools for monitoring disease status and patient responses to treatment of OA. Yet there is no lack of an evolving compendium of OA-related biomarkers, ever more fit-for-purpose, that could currently facilitate drug development for OA. We provide an abbreviated update and overview of specific soluble OA-related biomarkers for this new OARSI Primer on OA with OA-relevant examples encompassing the concepts of biomarker nomenclature, qualification, interpretation, measurement, reporting requirements, application to research, drug discovery and clinical care, and future needs for biomarker advancement.

Conclusion

Appropriate biomarkers should play a role at all stages of OA diagnosis, prognosis, drug development, and treatment. The future of OA biomarker research and development holds great promise as its foundation is increasingly robust.

中文翻译：

---

骨关节炎的临床监测：生物标志物

 客观的

骨关节炎 (OA) 生物标志物概述的目的是根据生物标志物研究人员多年来获得的经验，为非专业人士提供一个工具箱，以了解一般生物标志物及其在 OA 领域的用途。

 方法

自近十年前 OARSI 骨关节炎 (OA) 入门指南发布以来，我们提供了有关此主题的最新信息。

 结果

自上次更新以来，分子生物标志物的重要性在该领域已得到越来越多的认识，但尚未将 OA 相关生物标志物纳入临床实践中常规使用。目前缺乏针对 OA 的软骨保护治疗，损害了生物标志物作为监测疾病状态和患者对 OA 治疗反应的工具的潜在作用的评估、验证和鉴定。然而，不乏不断发展的 OA 相关生物标志物概要，它们越来越适合用途，目前可以促进 OA 药物的开发。我们为这个新的 OARSI OA 入门指南提供了特定可溶性 OA 相关生物标志物的简短更新和概述，以及 OA 相关示例，涵盖生物标志物命名法、资格、解释、测量、报告要求、研究应用、药物发现和临床的概念护理，以及生物标志物进步的未来需求。

 结论

适当的生物标志物应该在 OA 诊断、预后、药物开发和治疗的各个阶段发挥作用。 OA 生物标志物研究和开发的未来前景广阔，其基础日益坚实。